Edition:
India

Brainstorm Cell Therapuetics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.92USD
11 Dec 2017
Change (% chg)

$-0.10 (-2.49%)
Prev Close
$4.02
Open
$3.94
Day's High
$3.98
Day's Low
$3.90
Volume
36,369
Avg. Vol
13,362
52-wk High
$5.15
52-wk Low
$2.11

Chart for

About

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $75.75
Shares Outstanding(Mil.): 18.84
Dividend: --
Yield (%): --

Financials

BRIEF-Brainstorm Cell Therapuetics names Eyal Rubin CFO

* Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer

02 Nov 2017

BRIEF-Brainstorm reports Q3 loss per share of $0.13

* Q3 loss per share $0.13 Source text for Eikon: Further company coverage:

17 Oct 2017

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

16 Oct 2017

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV, Oct 16 BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

16 Oct 2017

BRIEF-Brainstorm reports Q2 loss per share of $0.06

* Q2 loss per share $0.06 Source text for Eikon: Further company coverage:

15 Aug 2017

BRIEF-BrainStorm Cell Therapuetics Q2 loss per share $0.06

* Q2 loss per share $0.06 Source text for Eikon: Further company coverage:

15 Aug 2017

BRIEF-Brainstorm announces agreement with University of California Irvine Medical Center

* Brainstorm announces agreement with university of california irvine medical center to participate in phase 3 trial of nurown® in als Source text for Eikon: Further company coverage:

25 Jul 2017

Earnings vs. Estimates